Twenty-Four-Month Blood Pressure Results After Renal Denervation Using Endovascular Ultrasound.
arterial hypertension
renal denervation
resistant hypertension
ultrasound renal denervation
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
15 08 2023
15 08 2023
Historique:
medline:
16
8
2023
pubmed:
15
8
2023
entrez:
15
8
2023
Statut:
ppublish
Résumé
BACKGROUND Renal denervation has proven its efficacy to lower blood pressure in comparison to sham treatment in recent randomized clinical trials. Although there is a large body of evidence for the durability and safety of radiofrequency-based renal denervation, there are a paucity of data for endovascular ultrasound-based renal denervation (uRDN). We aimed to assess the long-term efficacy and safety of uRDN in a single-center cohort of patients. METHODS AND RESULTS Data from 2 previous studies on uRDN were pooled. Ambulatory 24-hour blood pressure measurements were taken before as well as 3, 6, 12, and 24 months after treatment with uRDN. A total of 130 patients (mean age 63±9 years, 24% women) underwent uRDN. After 3, 6, 12, and 24 months, systolic mean 24-hour ambulatory blood pressure values were reduced by 10±12, 10±14, 8±15, and 10±15 mm Hg, respectively, when compared with baseline (
Identifiants
pubmed: 37581398
doi: 10.1161/JAHA.123.030767
pmc: PMC10492948
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e030767Références
Hypertension. 2015 Apr;65(4):766-74
pubmed: 25691618
Lancet. 2017 Nov 11;390(10108):2160-2170
pubmed: 28859944
EuroIntervention. 2022 Oct 07;18(8):e686-e694
pubmed: 35244604
JACC Cardiovasc Interv. 2023 Feb 13;16(3):367-369
pubmed: 36792266
J Am Heart Assoc. 2021 Nov 2;10(21):e022429
pubmed: 34713718
Hypertension. 2013 Feb;61(2):450-6
pubmed: 23283361
EuroIntervention. 2016 Jun 12;12(2):e282-9
pubmed: 27290688
EuroIntervention. 2020 May 20;16(1):89-96
pubmed: 32038027
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
JACC Cardiovasc Interv. 2012 Mar;5(3):249-58
pubmed: 22440489
EuroIntervention. 2022 Oct 07;18(8):e677-e685
pubmed: 35913759
Lancet. 2021 Jun 26;397(10293):2476-2486
pubmed: 34010611
Pflugers Arch. 2021 Oct;473(10):1617-1629
pubmed: 34232378
Lancet. 2022 Apr 9;399(10333):1401-1410
pubmed: 35390320
Lancet. 2018 Jun 9;391(10137):2335-2345
pubmed: 29803590
Circulation. 2019 Jan 29;139(5):590-600
pubmed: 30586691
Lancet. 2020 May 2;395(10234):1444-1451
pubmed: 32234534
EuroIntervention. 2015 Feb;10(10):1230-8
pubmed: 25349043
Am J Physiol Renal Physiol. 2022 Jun 1;322(6):F680-F691
pubmed: 35466689
Eur Heart J. 2019 Nov 1;40(42):3474-3482
pubmed: 30907413
Lancet. 2018 Jun 9;391(10137):2346-2355
pubmed: 29803589
J Hypertens. 2017 Jun;35(6):1310-1317
pubmed: 28441700
Lancet. 2009 Apr 11;373(9671):1275-81
pubmed: 19332353
Eur Heart J Qual Care Clin Outcomes. 2023 Sep 12;9(6):575-582
pubmed: 36057838
Am J Physiol Regul Integr Comp Physiol. 2016 May 1;310(9):R806-18
pubmed: 26911463
Eur Heart J Suppl. 2020 Nov 18;22(Suppl L):L160-L165
pubmed: 33239993
Lancet. 2010 Dec 4;376(9756):1903-9
pubmed: 21093036
Hypertension. 2015 Feb;65(2):393-400
pubmed: 25403610
Lancet. 2022 Oct 22;400(10361):1405-1416
pubmed: 36130612